UNSPSC 51386613: Hydrocortisone/urea

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.

UNSPSC 51386613 Hydrocortisone/urea is a Commodity code that nominally describes pharmaceutical topical treatments, but the recent state and local procurement activity tagged under this code does not reflect that scope. Seminole County, Florida's IFB 60459723LAS, posted in June 2026 with a July 26, 2023 response deadline, solicits naloxone and drug deactivation systems — products entirely outside the hydrocortisone/urea therapeutic category. The mismatch between the code's stated scope and the actual work being bought suggests either a data classification error on the county's side or a broader tagging issue in the underlying procurement system. State and local buyers do source pharmaceuticals and topical treatments through their health departments, community health facilities, and emergency-response programs, but this particular opportunity does not represent that activity.

With only one identifiable recent opportunity in the source data, visibility into the broader market for hydrocortisone/urea procurement under this code is severely limited. Seminole County's solicitation is the sole recent activity; no pattern of issuing bodies, geographic concentration, or recurring demand emerges. Procurement professionals should verify the UNSPSC classification against the vendor master data and opportunity descriptions in their target jurisdictions before committing resources to this code, as the mismatch between nominal scope and tagged opportunity suggests the code may not be a reliable filter for actual hydrocortisone/urea demand in state and local markets.